KEYTRUDA 25 mg/mL concentrate for solution for infusion, ivonescimab, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin 10 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion., Pazenir 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion
SMT112-3003
Phase 3 small_molecule active
Quick answer
KEYTRUDA 25 mg/mL concentrate for solution for infusion, ivonescimab, Paclitaxel Ribosepharm 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin 10 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion., Pazenir 5 mg/ml powder for dispersion for infusion., ALIMTA 500 mg powder for concentrate for solution for infusion for Metastatic Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Summit Therapeutics
- Indication
- Metastatic Non-small Cell Lung Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active